RSV season runs into spring

An unusually late respiratory syncytial virus (RSV) season is extending into the spring months across the United States, prompting several states to broaden eligibility for preventive treatments in children as public health officials and pediatric experts urge continued vigilance among parents. This atypical pattern, defying the virus's traditional winter peak, has created an extended period of elevated risk for vulnerable infants and young children. The prolonged season has led state health departments to adjust their public health strategies, specifically by extending the availability of monoclonal antibody treatments like Beyfortus (nirsevimab). These preventive shots, typically administered during the fall and winter, are now being recommended for a wider window to protect infants from severe illness. The delay is attributed to complex factors, including the lingering effects of pandemic-era immunity gaps and shifting seasonal patterns of respiratory viruses, which have disrupted the historical predictability of RSV circulation. Health experts emphasize that despite the arrival of warmer weather, RSV remains a significant threat. They are advising parents and caregivers to maintain awareness of symptoms—such as labored breathing, wheezing, and decreased fluid intake—and to seek medical attention promptly if they suspect infection. The extended season highlights the ongoing challenges in managing post-pandemic respiratory virus epidemiology and underscores the importance of flexible public health responses to protect pediatric populations from severe outcomes.